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tended to continuously improve the management of
JIA patients. 
Keywords: Recommendations; Juvenile idiopathic
arthritis; Biological agents.
IntroductIon
Juvenile Idiopathic Arthritis (JIAs) incorporates a hete -
rogeneous group of arthritis of unknown etiology, be-
ginning before the age of 16 and persisting for at least
6 weeks1. The International League of Associations for
Rheumatology (ILAR) classifies childhood arthritis into
7 mutually exclusive categories: systemic arthritis
(sJIA), oligoarthritis (oJIA), polyarthritis (pJIA) rheu -
matoid factor (RF) positive, pJIA RF negative, enthesi-
tis-related arthritis (ERA), juvenile psoriatic arthritis
(jPsA) and undifferentiated arthritis. Beyond the first 6
months oJIA can be further classified as persistent oJIA,
if still less than 5 joints are involved, or extended
oligoarticular (eoJIA), if involvement of ≥5 joints 
occurs. In the case of sJIA, systemic features may per-
sist or the disease may evolve into polyarthritis.
When conventional therapies fail to achieve disease
control, biological agents proved to be effective in re-
ducing JIA inflammatory burden2.
In 2007, the Portuguese Society of Rheumatology
published national recommendations for the use of bio -
logics in JIA, aiming to optimize the management of
children and adolescents with JIAs3. The recommen-
dations were revised in 2011 and covered eligibility,
monitoring, switching and safety procedures before and
while on biological therapy4. Based on the progresses in
this field and the new licensed biologics, the recom-
mendations are now updated.
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AbstrAct 
Objective: To provide evidence-based guidance for the
rational and safe prescription of biological therapies in
children and adolescents with juvenile idiopathic
arthritis (JIAs), considering the latest available evidence
and the new licensed biologics.
Methods: Rheumatologists and Pediatricians with ex-
pertise in Pediatric Rheumatology updated the recom-
mendations endorsed by the Portuguese Society of
Rheumatology and the Portuguese Society of Pediatrics
based on published evidence and expert opinion. The
level of agreement with final propositions was voted
using an online survey.
Results: In total, 20 recommendations to guide the use
of biological therapy in children and adolescents with
JIAs are issued, comprising 4 general principles and 16
specific recommendations. A consensus was achieved re-
garding the eligibility and response criteria, maintenance
of biological therapy, and procedures in case of non-res -
ponse, for each JIA category. Specific recommendations
concerning safety procedures were also updated.
Conclusions: These recommendations take into ac-
count the specificities of each JIA category and are in-
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mEthods
The recommendations were elaborated by the Pedia -
tric Rheumatology Working Group of the Portuguese
Society of Rheumatology and the Rheumatology Sec-
tion of the Portuguese Society of Pediatrics. A steering
group constituted by Rheumatologists and Pediatri-
cians with expertise in the management of JIA patients,
defined the relevant questions and a literature search
was performed, through November 2015, using pri-
marily MEDLINE. The retrieved evidence was dis-
cussed and a set of new recommendations was draft-
ed. All propositions were extensively debated and fi-
nal recommendations formulated. The level of agree-
ment was voted online, using a 1–10 scale with a vote
of 1 meaning total disagreement and 10 meaning full
agreement with the recommendation. A draft propo -
sal of the final manuscript was afterwards presented
for detailed review and final wording.
rEsuLts
In line with the 2011 recommendations we present the
general principles and then the guidance for starting,
maintaining and stopping biologics (Table I). More em-
phasis is now placed on the treatment of each JIA ca -
tegory and on newly approved drugs or new indica-
tions. Off-label prescription is also addressed.
gEnErAL prIncIpLEs
1. rheumatologists and pediatricians 
with experience in pediatric rheumatology 
are the specialists who should care for 
JIA patients 
An experienced pediatric rheumatology team provides
the best care for children with arthritis5. Biologics
should only be prescribed in specialized clinics run by
rheumatologists and/or pediatricians with document-
ed expertise in pediatric rheumatology.
2. the treatment goal is to achieve 
normal function, quality of life and social
participation, through tight disease 
control. JIA activity must be regularly
monitored using valid instruments and
should be used to guide appropriate
treatment adjustments
The rate of active JIA progressing into adulthood is still
high, as it is the risk for serious and lifelong compli-
cations6,7. Furthermore, approximately 12% to 38% of
JIA patients will develop uveitis8,9 and 50% to 75% of
tAbLE I. rEcommEndAtIons for thE usE of bIoLogIcAL thErApy In JuvEnILE IdIopAthIc ArthrItIs
Level Agreement 
General principles evidence Mean(SD)
1 Rheumatologists and Pediatricians with experience in pediatric rheumatology are 9.6 (1.2)
the specialists who should care for JIA patients 
2 The treatment goal is to achieve normal function, quality of life and social participation, 9.8 (0.5)
through tight disease control. JIA activity must be regularly monitored using valid 
instruments and should be used to guide appropriate treatment adjustments
3 A definitive diagnosis of JIA and sustained articular, systemic or ocular inflammation are 9.5 (0.7)
required when starting a biologic
4 The biologic choice must take into account the JIA phenotype 9.6 (0.7)
Biological therapy for polyarticular course JIA
5 In pJIA patients who failed MTX in recommended doses for at least 3 months, unless 1b; 3 9.2 (0.9)
contraindicated, or toxicity/ intolerance occurs, a bDMARD should be considered. 
A bDMARD can be initiated earlier or in patients with few active joints taking into 
account prognostic factors and the pediatric rheumatologist opinion
6 TNFi, tocilizumab and abatacept are recommended for pJIA patients with inadequate 1b; 2b 9.4 (0.9)
response to csDMARDs. Rituximab may be considered in case of inadequate response 
to the previous bDMARDs
Continues on the next page
ÓRGÃO OfICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
196
RecoMMendationS foR the uSe of biologicS in Jia – 2016 update
tAbLE I. contInuAtIon
Level Agreement 
General principles evidence Mean(SD)
7 Assessment of response and the decision to maintain treatment should be performed no 1b; 5 8.9 (1.1)
longer than 3 months after starting a bDMARD and biologic treatment should only be 
maintained in patients who achieve at least an ACRPed 50 or JADAS response
Biological therapy for systemic course JIA
8 Systemic JIA is eligible for treatment with biologics if sustained severe systemic features 1b; 5 9.6 (0.7)
persist regardless of concurrent therapy. Steroid dependence also constitutes an indication 
for bDMARD
9 IL-1 inhibitors (anakinra or canakinumab) or tocilizumab are recommended for refractory 1b 9.3 (0.6)
and/or steroid dependent sJIA
10 Assessment of response and the decision to maintain treatment should be performed 1b; 5 8.6 (1.3)
no longer than 1 month after starting a biologic in sJIA. Biologic treatment should only 
be maintained in patients who are free of systemic manifestations 
Biological therapy for enthesitis-related arthritis
11 Biological therapy should be considered in active polyarthritis and/or active enthesitis 1b 9.2 (1.0)
ERA patients with inadequate response to NSAIDs, at least one csDMARD, including  
MTX, and glucocorticoid injections, if appropriate
12 TNFi are recommended for refractory ERA 1b 9.6 (0.2)
13 Assessment of response and the decision to maintain bDMARD should be performed 1b; 5 8.9 (1.1)
no longer than 3 months after starting treatment in ERA patients. Biologic treatment 
should only be maintained in patients who achieve at least an ACRPed 50 and have 
documented improvement of enthesitis 
Biological therapy for juvenile psoriatic arthritis
14 Biological therapy should be considered in jPsA patients who failed at least one csDMARD, 1b 9.5 (0.7)
including MTX in recommended doses for at least 3 months, unless contraindication, 
toxicity or intolerance
15 TNFi are recommended for refractory jPsA. Other biologics may be considered in case 1b 9.4 (0.8)
of inadequate response and/or major cutaneous involvement
16 Assessment of response and the decision to maintain treatment should be performed no 1b; 5 8.9 (0.9)
longer than 3 months after starting a biologic in jPsA patients. Biologic treatment should 
only be maintained in patients who achieve at least an ACRPed 50 and have documented 
improvement of extra-articular involvement (skin, dactilytis and enthesitis if applicable)
Tapering and stopping biological therapy
17 Reducing and stopping biologic therapy might be attempted if sustained remission is 2b 9.1 (1.2)
achieved and maintained for more than 24 months
Safety considerations
18 All patients must be screened for tuberculosis, HIV, Hepatitis B and C virus infection 2b 9.9 (0.5)
prior to biological therapy
19 Biological therapy should be discontinued prior to elective surgery and re-introduced 4 9.7 (0.6)
only in the absence of infection and after satisfactory healing of surgical wound
20 Biological therapy should not be initiated in presence of active infection and must be 4 9.8 (0.5)
discontinued until any serious infection is resolved
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those with severe uveitis will develop visual impairment
secondary to cataract, glaucoma, band kera topathy or
macular pathology10,11. The prevention of irreversible
damage and functional disability is the ultimate treat-
ment goal, for which timely control of inflammation is
indispensable5. Frequent assessment of disease activity
is necessary in order to implement a treat-to-target strat-
egy, aiming to achieve and maintain tight control, with
treatment escalation if a target is not reached or if the
disease relapses12. Early efficacious therapy results in
clinical inactive disease in a larger number of patients,
even with severe JIA13. Clinical evaluation of JIA patients
should include the assessment of articular and extra-ar-
ticular disease activity[1], as well as the evaluation of
function and quality of life at regular time points. In or-
der to standardize procedures across different pediatric
rheumatology clinics, the monitoring of JIA should be
done according to the Rheumatic Diseases Portuguese
Register (Reuma.pt)/ /JIA protocol16.
3. A definitive diagnosis of JIA and sustained
articular, systemic or ocular inflammation are
required when starting a biologic
A rheumatologist or a pediatrician with expertise in
rheumatic diseases of childhood must establish a
definitive diagnosis of JIA before starting biological
therapy. JIA patients are eligible for biological therapy
when active disease, defined as articular, systemic 
or ocular inflammation, persists despite appropriate
conventional treatment as outlined in Figure 1, or when
unacceptable side effects related to these me dications
are present. Children starting biologics should be re -
gistered and longitudinally followed-up in Reuma.pt.
4. the biologic choice must take into account
the JIA phenotype
There are currently six biologics, with different modes
of action, approved for use in JIA patients (Table III):
three tumor necrosis factor (TNF) inhibitors (adali-
mumab, etanercept and golimumab), one interleukin
(IL)-1 inhibitor (canakinumab), one IL-6 inhibitor
(tocilizumab) and one T-cell co-stimulation blocker
(abatacept). Yet, off-label use of other biologic disease
modifying anti rheumatic drugs (bDMARDs) is fre-
quent in clinical practice.
TUMOR NECROSIS FACTOR INHIBITORS (TNFi)
Etanercept is a fusion protein that had first proven effi-
cacy in pJIA17. More recently, its efficacy was demons -
trated in eoJIA (2-17 years), ERA and jPsA (12-17
years)18. Data from registries also documented its ef-
fectiveness with an encouraging safety profile19. Al-
though the risk of severe adverse events seems higher
with etanercept compared to MTX, the risk of malig-
nancies was not significantly increased20. Patients on
etanercept monotherapy developed more frequently
incident inflammatory bowel disease and uveitis (0.5
and 0.8 events/100 years) than patients treated with
etanercept in combination with MTX (0.1 and 0.2
events/100 years) or MTX alone (0.03 and 0.1
IAG injections± NSAIDs
MTXOther csDMARDs
ERA
IAG injections± NSAIDs
oJIA
MTXOther csDMARDs
± low dose GC± IAG injections
pJIAeoJIA 
IAG injections± NSAIDs
MTXOther csDMARDs
jPsA
NSAIDssystemic GC
± MTX
sJIA
IAG injections
± NSAIDs
MTX
Other csDMARDs
ERA
IAG injections
± NSAIDs
oJIA
MTX
Other csDMARDs
± low dose GC
± IAG injections
pJIA
eoJIA 
IAG injections
± NSAIDs
MTX
Other csDMARDs
jPsA
NSAIDs
systemic GC
± MTX
sJIA
fIgurE 1. Conventional treatment according to JIA phenotype
Legend: JIA – Juvenile idiopathic arthritis; oJIA – oligoarticular JIA; pJIA – polyarticular JIA; eoJIA – extended oligoarticular JIA;
ERA – enthesitis related arthritis; jPsA – juvenile psoriatic arthritis; sJIA – systemic JIA; IAG – intra-articular glucocorticoids; 
GC – glucocorticoids; NSAIDs – non-steroidal anti-inflammatory drugs; MTX – methotrexate
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events/100 years). Yet, the number of new events is
very low21,22. A controlled pilot trial did not demons -
trate superiority of etanercept over placebo in JIA as-
sociated uveitis23 and a systematic review confirmed
that etanercept is ineffective in chronic anterior
uveitis24. Experience in treating patients below 2 years
old is limited and the 13 patients from the BIKER re -
gister (4 sJIA, 4 eoJIA, 1 oJIA and 4 pJIA RF negative)
constitute a valuable source of clinical experience25. At
last observation, 6/11 patients reached ACRPed 70 res -
ponse. The rate of adverse events (AE) in this age group
is higher than previously described in older chil-
dren25,26. Etanercept use in sJIA has been also reported
and it is more efficacious in controlling arthritis than
systemic features. Etanercept has been described either
as treatment or as a trigger for the development of
macrophage activation syndrome (MAS)27-29. A con-
founding by indication is plausible in this association.
Adalimumab is a fully human monoclonal antibody
that binds to TNF. Recently, a multicenter open-label,
phase 3b study in patients with active JIA, was con-
ducted to assess the safety of adalimumab in patients
with moderately to severely active pJIA, aged 2 to <4
years old or ≥4 years old weighting <15 kg30. At week
96, 92% of patients achieved ACRPed 30 and 77%
achieved ACRPed 70. No new safety signals occurred,
namely there were no opportunistic infections/tuber-
culosis, malignancies, or deaths reported. A multicen-
ter, randomized placebo-controlled (RCT) parallel study
in active and refractory juvenile onset ankylosing
spondylitis (AS) documented higher response rates in
the adalimumab group compared to placebo. At week
12 the BASDAI score decreased by 65%, back pain de-
creased by 50% and BASFI score by 47%, while CHAQ-
-DI score improved by 65%, all being statistically sig-
nificant. There was no difference in the rate of AEs be-
tween groups. Injection site reactions were the most
common AE31. Data from registries suggest adalimu mab
to be effective in the treatment of JIA associated uveitis,
as well as in reducing the rate of uveitis flares32,33. A
meta-analysis including 229 children with JIA associa -
ted uveitis has shown that adalimumab and infliximab
have similar efficacy and are superior to etanercept. In
the 40 months follow-up, uveitis more commonly
remai ned in remission in those treated with adalimu -
mab compared with infliximab (60% vs 18.8%)34. The
results from a RCT to assess the efficacy of adalimu mab
in addition to MTX for the treatment of JIA associa ted
uveitis are expected in the near future35.
Infliximab is a chimeric monoclonal antibody not
appro ved for JIA. A RCT showed improvement with
infliximab in the majority of patients at 1 year, but did
not meet its primary endpoint36. The clinical experien -
ce in JIA37,38 and uveitis39 demonstrates infliximab uti -
lity. Small observational studies in juvenile spondy-
loarthritis refractory to standard treatment document-
ed good long-term control of axial disease, peripheral
arthritis and enthesitis with infliximab40,41.
Golimumab is a human monoclonal antibody bin -
ding both soluble and membrane bound forms of TNF
recently approved for JIA. GO-KIDS, a three part with-
drawal RCT, showed a 87% ACRPed 30 response rate
during the open-label first 16 weeks on golimumab,
but failed to meet its primary endpoint42. However, the
Committee for Medicinal Products for Human Use of
the European Medicines Agency adopted a positive
opinion, recommending the use of subcutaneous goli-
mumab in combination with MTX for the treatment of
pJIA in children with a body weight of at least 40 kg,
who have responded inadequately to previous therapy
with MTX43. In addition, case reports suggest that goli-
mumab might be useful for the treatment of refractory
JIA associated uveitis44.
Certolizumab is a pegylated Fab’fragment of a hu-
tAbLE II. JAdAs And cJAdAs cut-off vALuEs for
oJIA And pJIA dIsEAsE ActIvIty stAtEs
oJIA pJIA
Disease activity states according 
to JADAS
Inactive disease ≤1 ≤1
Physician-assessed remission ≤2 ≤2
Parent-assessed remission ≤2.3 ≤2.3
Child-assessed remission ≤2.2 ≤2.2
Minimal disease activity ≤2 ≤3.8
Parent acceptable symptom state ≤3.2/3.5 ≤5.2/5.4*
Child acceptable symptom state ≤3 ≤4.3/4.5*
High disease activity** >4.2 >8.5/10.5*
Disease activity states according 
to cJADAS***
Low disease activity ≤1.5 ≤2.5
Moderate disease activity 1.51-4 2.51-8.5
High disease activity >4 >8.5
Cut-off values apply to all versions of the Juvenile Arthritis Disease
Activity Score (JADAS) versions, unless otherwise indicated.
*Cut-off value for JADAS27/cut-off value for JADAS10 and JADAS71.
**Cut-off values only apply to non-systemic JIA categories.
***Cut-off values for non-systemic JIA using the clinical Juvenile
Arthritis Disease Activity Score (cJADAS) 
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manized TNF inhibitor antibody, not approved for JIA.
The results of an open label phase 3 clinical trial in chil-
dren with pJIA aged 2-17 years were not yet publi shed45.
INTERLEUKIN-1 INHIBITORS
Canakinumab is a monoclonal antibody that binds se-
lectively to IL-1β. It was first approved for cryopirin-
associated periodic syndromes and later for sJIA in chil-
dren aged 2 years and older, with systemic features re-
fractory to NSAIDs and glucocorticoids. It can be used
alone or in combination with MTX. Data from a phase
II dosage escalation open-label trial in 23 children re-
ceiving a single injection of canakinumab subcuta-
neously showed an immediate response, achieving at
least an ACRPed 50 on day 15. Remission was observed
in 18% of patients. Six of 11 non-responders to anakin-
ra achieved at least an ACRPed 50 on day 15, after a sin-
gle dose of canakinumab. AE were mild to moderate in
severity and consisted mainly in infections and gas-
trointestinal symptoms. Three SAE occurred46. The evi -
dence for approval was based on 2 RCTs47. In the place-
bo-controlled phase, there was a statistically signi ficant
relative risk reduction in time to flare of sJIA of 64%
with canakinumab compared with placebo. Parti cular
risks identified were serious infections, neutro penia,
leukopenia and thrombocytopenia. In the poo led sJIA
population, 85% of children and young people who re-
ceived canakinumab experienced at least 1 adverse
event. SAE were seen in 17% of this population.
Anakinra binds competitively to the IL-1 receptor,
without inducing a stimulatory signal. A French retros -
pective study in 35 adults and children (20 with sJIA
and 15 with adult-onset Still’s disease) demonstrated
improvement in 75% of sJIA patients48. All had
refracto ry active arthritis and were previously treated
with glucocorticoids, MTX, TNFi and/or thalidomide.
Systemic symptoms remitted in 14 of 15 cases and the
steroid dose was reduced in 50%. Two patients dis-
continued therapy because of severe skin reactions and
another two due to infection. In 2011, a multicenter,
randomized, double blind, placebo-controlled trial in
12 patients with sJIA showed an immediate and bene-
ficial effect of anakinra on systemic features, as well as
on joint inflammation49. No differences in AE were
obser ved between groups. The efficacy of anakinra as
a first-line disease-modifying therapy was also docu-
mented in sJIA, in some cases used as monotherapy50.
Active arthritis resolved less frequently and less rapi dly.
Complete response was observed in 59% of the pa-
tients, while another 39% exhibited a partial response.
Inactive disease was achieved in 80% patients on
anakinra monotherapy. Although anakinra has very
good results in the short term, these may not be sus-
tained in the long term. Another caveat is the need for
a daily injection, often associated with pain and injec-
tion site reactions. Furthermore, the risk of infections
seems increased. Rare cases of MAS were described in
patients taking anakinra. Conversely, there are MAS
case reports successfully treated with anakinra51,52. As
for etanercept confounding by indication might be re-
lated to the occurrence of this MAS cases.
IL-6 SIGNALING INHIBITION
Tocilizumab is a recombinant humanized anti-IL-6R
monoclonal antibody that binds to membrane and
solu ble IL-6R, inhibiting IL-6–mediated signaling. It is
approved for the treatment of sJIA and for the treat-
ment of pJIA in children aged 2 years and older.
A phase 3 trial of TCZ in active sJIA patients, who
were inadequate responders to NSAIDs and glucocor-
ticoids, showed ACRPed 30, 70 and 90 responses of
85, 80 and 59%, respectively. During treatment, pa-
tients experienced significant catch-up growth, nor-
malization of insulin-like growth factor 1 (IGF-1) le -
vels, and bone balance favoring bone formation53. Of
notice, there was also a beneficial effect in patients who
had been previously treated with anakinra54. The ex-
tension phase demonstrated sustained effectiveness,
good tolerability and a low discontinuation rate in the
long-term treatment of children with sJIA. Safety issues
include serious infections, neutropenia and increased
liver enzymes55. A withdrawal RCT that enrolled 188
patients with pJIA (RF positive and RF negative) or 
eoJIA, who had failed or were intolerant to MTX,
showed that 89% of patients achieved ACRPed 30,
62% ACRPed 70, and 26% ACRPed 90 response. Con-
current MTX decreased the risk of flare. The rate of AEs
in the exposed population was 479.8 per 100 patient-
-years, most AEs were mild or moderate. The rate of se-
rious infections (4.9/100 patient-year) was lower than
the one reported for children with sJIA56.
Tocilizumab has been used successfully in cases of
uveitis associated with JIA unresponsive to prior TNF
blockade57,58 and in refractory idiopathic uveitis59,60. Based
on anecdotal reports, tocilizumab might also be useful in
the treatment of amyloidosis secondary to JIA61,62.
CO-STIMULATORY BLOCKADE
Abatacept is approved for pJIA in combination with
MTX, after failure of a TNFi. However, abatacept may
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be an alternative to a TNFi, as first-line bDMARD, in
particular circumstances. The first withdrawal RCT in
children with JIA who failed previous treatments
showed that abatacept decreased the num ber of arthri-
tis flares63. Of TNFi naïve patients, 76% achieved
ACRPed 30, 60% ACRPed 50, and 36% ACRPed 70
response, and 13% had inactive disease. Patients pre-
viously exposed to TNFi respond less frequently to
abatacept (ACRPed 30/50/70 response in 39%/25%/
/11%, respectively). Improve ments in health-related
quality of life and sleep quality were also observed in
the abatacept treated group64. Some recent data also
suggest that abatacept might have a role in the treat-
ment of refractory cases of JIA-associated uveitis65,66.
B CELL DEPLETION
Rituximab is not approved in JIAs, but based on seve -
ral case series it can be an option, after failure of other
biologics. An open label study including 55 children
with severe pJIA or sJIA, documented a significant re-
duction of systemic manifestations and arthritis, with
52% of patients achieving remission by week 4867. Ritu -
ximab seems also to be effective for the treatment of re-
fractory JIA associated uveitis68. It should be used with
caution in children as long-lasting B-cell depletion is
not uncommon following this therapy69.
POSSIBLE FUTURE OPTIONS
A long-term open-label study of tofacitinib, a JAK in-
hibitor that blocks signalling of multiple cytokines, is
currently enrolling JIA patients to assess safety and to -
lerability in these patients70. Ustekinumab, an IL12/23
inhibitor, is effective in the treatment of psoriatic arthri-
tis and psoriasis, inclusively in adolescents71, yet not
studied in JIA. Also, there is no reported experience
with the IL-17 inhibitor secukinumab in children.
bIoLogIcAL thErApy for poLyArtIcuLAr
coursE JIA
5. In pJIA patients who failed mtX in
recommended doses for at least 3 months,
unless contraindicated, or toxicity/intolerance
occurs, a bdmArd should be considered. 
A bdmArd can be initiated earlier or in 
patients with few active joints taking into
account prognostic factors and the pediatric
rheumatologist opinion
A bDMARD should be started if there is an inadequate
response after 3-6 months of treatment with conven-
tional synthetic (cs)DMARDs, one of which must be
MTX 15-20 mg/m2/week for at least 3 months, unless
contraindicated, or toxicity/intolerance occurs. Leflu -
nomide can be an alternative in the absence of poor
prog nostic features[2]75. However, for patients with
poor prognostic factors an earlier start of a bDMARD
may be appropriate (Figure 2), based on the concept of
a window of opportunity13,76. The decision to initiate a
bDMARD earlier or in patients with fewer active joints
should be made on an individual basis taking into
consi deration prognostic features, functional impair-
ment, drug side effects and the pediatric rheumatolo-
gist opinion.
6. tnfi, tocilizumab and abatacept are
recommended for pJIA patients with
inadequate response to csdmArds. 
rituximab may be considered in case 
of inadequate response to the previous 
bdmArds
After failure of the maximum tolerated MTX dose or
after failing a second csDMARD, if judged appropriate,
TNFi or tocilizumab should be considered for active
pJIA. Abatacept is indicated in pJIA patients unres -
ponsive to TNFi. Rituximab should be reserved for re-
fractory cases (Figure 2).
7. Assessment of response and the decision to
maintain treatment should be performed no
longer than 3 months after starting a bdmArd
and biologic treatment should only be
maintained in patients who achieve at least an
Acrped 50 or JAdAs response
Since the development of preliminary definitions of im-
provement77, the ACRPed response criteria have be-
come the primary outcome measures in therapeutic tri-
als in pJIA. The ACRPed includes PhGA measured in a
10 cm visual analogue scale (VAS), PGA measured in a
10 cm VAS, number of active joints, number of joints
with limited motion, CHAQ and measurement of an
acute phase reactant (CRP or ESR). This is a useful ins -
trument for evaluating improvement following a gi ven
treatment, but the “core set” has not been valida ted for
comparison between patients, and does not provide
the level of disease activity. Instead, the composite score
JADAS, can be used to assess treatment response on an
individual level (Table II).
Maintenance of treatment requires that a meaning-
ful clinical response is reached. The choice of a 
3-month period is based on the time to achieve respon -
se observed in phase 3 trials with biologics in pJIA.
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ACRPed 50 response, defined as at least 50% im-
provement in 3/6 core response variables, with no more
than 1 of the remaining measures worsening by >30%,
must be reached in order to maintain biological thera-
py. Nevertheless, a higher response level should be
aimed such as remission or a state of minimal clinical di -
sease activi ty (MDA), defined as PhGA<=2.5 cm and
swollen joint count of 0 in patients with oligoarthritis, or
as PhGA<=3.4 cm, PGA<=2.1 cm, and swollen joint
count <=1 in patients with polyarthritis78. Alternatively,
JADAS improvement can be used, defined by a minimal
decrease in the JADAS10 score according to baseline class:
low by 4, moderate by 10 and high by 1779.
If a patient fails the first biologic agent there is some
evi dence that a second biologic can be used with suc-
cess80.
bIoLogIcAL thErApy for systEmIc coursE 
JuvEnILE ArthrItIs
8. systemic JIA is eligible for treatment 
with biologics if sustained severe systemic 
features persist regardless of concurrent
therapy. steroid dependence also constitutes
an indication for bdmArd
The initial treatment depends on the severity of clini -
cal manifestations and usually includes NSAIDs and
systemic glucocorticoids, as shown in Figure 3. Indi-
cations for glucocorticoids ab initio include sympto -
matic serositis, myocarditis, pleural effusions, pneumo -
nitis, severe anemia and MAS. MTX should be started
if active joints are present. Sustained severe systemic
features that persist despite systemic glucocorticoids,
with or without csDMARD, is an indication for starting
MTX±IAG injections± low doses systemic GC
Disease control within 3-6 monthsPoor prognostic features
Change oradd anothercsDMARD±IAG
injections 
Switch to a 2nd TNFi or tocilizumab or abatacept
Add TNFi ortocilizumab
Disease controlwithin 3 months
Disease controlwithin 3 months
Continue
Continue
Consider other switch
Taper and stop GCContinue MTXYESYES
YES
YES
NO
NO
NO
NO
MTX
±IAG injections
± low doses systemic GC
Disease 
control within 
3-6 months
Poor 
prognostic 
features
Change or
add another
csDMARD
±IAG
injections
 
Switch to a 
2nd TNFi or 
tocilizumab 
or abatacept
Add TNFi or
tocilizumab
Disease control
within 3 months
Disease control
within 3 months
Continue
Continue
Consider 
other switch
Taper and 
stop GC
Continue MTX
YES
YES
YES
YES
NO
NO
NO
NO
fIgurE 2. Polyarticular course JIA 
Legend: JIA – Juvenile idiopathic arthritis; MTX-methotrexate; IAG – intra-articular glucocorticoids; GC – glucocorticoids;
csDMARD – classic synthetic Disease Modifying Anti Rheumatic Drugs; TNFi – tumour necrosis factor inhibitor
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NSAIDs± Systemic GC± MTX
Diseasecontrol within1 monthPersistentsystemicfeatures
Treataccordingto diseasecourse
Switch totocilizumab or IL-1inhibitor
Add IL-1 inhibitoror tocilizumab
Disease controlwithin 1 month
Disease controlwithin 1 month
Continue
Continue
Consider other switchAdd calcineurin inhibitor?
Stop NSAIDsTaper andstop GC
YES YES
YES
YES
NO
NO
NO
NO
NSAIDs
± Systemic GC
± MTX
Disease
control within
1 month
Persistent
systemic
features
Treat
according
to disease
course
Switch to
tocilizumab 
or IL-1
inhibitor
Add IL-1 inhibitor
or tocilizumab
Disease control
within 1 month
Disease control
within 1 month
Continue
Continue
Consider other switch
Add calcineurin inhibitor?
Stop NSAIDs
Taper and
stop GC
YES
YES
YES
YES
NO
NO
NO
NO
fIgurE 3. Systemic JIA with active systemic features  
Legend: JIA – Juvenile idiopathic arthritis; MTX-methotrexate; GC – glucocorticoids; NSAIDs – non steroidal anti inflammatory
drugs
tAbLE III. bIoLogIcs ApprovEd for thE trEAtmEnt of JIA pAtIEnts
Approved Indication Age/body weight Dosis
Abatacept pJIA with inadequate response to TNFi.
≥6 years 10 mg/kg 4/4 week, i.v.
In combination with  MTX
Adalimumab pJIA ≥2 years 24 mg/m2 2/2 week s.c.
ERA ≥6 years (2-12 years)
Canakinumab SJIA ≥2 anos 2 or 4 mg/Kg 4/4 week s.c.
Etanercept pJIA ≥2 years
ERA ≥12 years 0.8 mg/kg/week s.c.
jPsA ≥12 years
Golimumab pJIA in combination with MTX ≥ 40 Kg 50 mg once a month s.c.
Tocilizumab sJIA
≥2 years
8 or 12 mg/Kg 2/2 week i.v.
pJIA 8 or 10 mg/kg 4/4 week s.c.
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a biologic. Besides, when JIA control is dependent on
moderate/high doses of systemic glucocorticoids, star -
ting a biologic is of utmost importance to prevent
steroid induced irreversible side effects.
9. IL-1 inhibitors (anakinra or canakinumab) 
or tocilizumab are recommended for
refractory and/or steroid dependent sJIA
IL-1 and IL-6 play a central role in the inflammatory
process underlying sJIA and the inhibition of these cy-
tokines has proved very effective in the control of sys-
temic inflammation47,81,82. IL-1 inhibitors or tocilizu -
mab can be used in addition to MTX or as monothe rapy
in refractory systemic JIA. There is good evidence of
reduction and discontinuation of steroids in patients
treated with these biologics47,48,55.
10. Assessment of response and the decision 
to maintain treatment should be performed 
no longer than 1 month after starting a 
biologic in sJIA. biologic treatment should 
only be maintained in patients who are free 
of systemic manifestations
IL-1 and IL-6 inhibitors provide prompt clinical
respon se and normalization of acute phase reactants
within the first days or weeks of treatment. In a multi-
center trial involving 24 patients, fever and rash re-
solved very rapidly in >95% of patients and C-reactive
protein (CRP) and ferritin normalized within 1 month
in >80% of the patients after starting anakinra49. Appro -
ximately 60% of sJIA patients achieved ACRped 50 res -
ponse 15 days after the first injection of canakinumab46.
Acute phase reactants and fever rapidly normalized 2
weeks after the first infusion of tocilizumab and 52%
of patients were able to discontinue oral glucocorti-
coids54.
In case of persistent systemic manifestations, bDMARD
must either be switched or the dose adjusted.
bIoLogIcAL thErApy for EnthEsItIs-rELAtEd
ArthrItIs
11. biological therapy should be considered 
in active polyarthritis and/or active enthesitis
ErA patients with inadequate response to
nsAIds, at least one csdmArd, including mtX,
and glucocorticoid injections, if appropriate
Initiation of a biologic is suitable for patients who have
failed MTX in a dose of 15-20 mg/m2/week for at least 3
months. Sulfasalazine can also be attempted before bio-
logical therapy. A few controlled trials showed its effica-
cy in a daily dose of 40-60 mg/kg/day, particularly in
ERA and in arthritis associated with inflammatory bo wel
disease, with acceptable short-term safety profiles83-85.
Intra articular glucocorticoid (IAG) injections should be
considered. Initiation of a biologic is also recommen ded
for patients who maintain active axial disease despite
having failed two consecutive NSAIDs, at maximum re -
commended doses, for 1-3 months (Figure 4).
12. tnfi are recommended for refractory ErA
Both adalimumab and etanercept demonstrated supe-
riority compared to placebo in the treatment of refrac-
tory ERA in double blind RCTs. The main outcomes
included ACRPed 30, 50, 70 and 90, the number of
tender joints, swollen joints and the number of tender
enthesis sites86,87. Moreover, TNF blockade is particu-
larly useful when there is axial disease31. In observa-
tional studies, anti-TNF treatment in ERA refractory to
standard treatment results in good disease control. Out-
comes included joint and enthesitis counts, as well as
axial disease assessment using BASDAI and BASFI41.
13. Assessment of response and the decision to
maintain bdmArd should be performed no longer
than 3 months after starting treatment in ErA
patients. biologic treatment should only be
maintained in patients who achieve at least an
Acrped 50 and have documented improvement
of enthesitis 
Maintenance of treatment requires that a meaningful
clinical response is reached. ACRPed 50 response and
reduction of the number of painful enthesis sites by
50% must be obtained in order to maintain ongoing
biological therapy. Although axial disease is uncom-
mon in young children, it can occur as part of the spec-
trum of juvenile spondyloathritis88. A major clinical res -
ponse, defined as a 50% improvement or more of the
initial BASDAI, should be achieved in patients with pre-
dominantly axial involvement. The reason to choose a
3-month period is based on the time to achieve res -
ponse observed in phase 3 trials with biologics in ERA.
bIoLogIcAL thErApy for JuvEnILE psorIAtIc
ArthrItIs
14. biological therapy should be considered in
jpsA patients who failed at least one csdmArd,
including mtX in recommended doses for at
least 3 months, unless contraindication,
toxicity or intolerance
The treatment algorithm for jPsA is similar to that em-
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ployed in other JIA categories, although the evidence
for conventional treatment is mostly from adult PsA.
NSAIDs are often employed initially and individual
large joints can be treated effectively with IAG injec-
tions. In adult PsA patients MTX is effective for pe-
ripheral arthritis, with significant improvements in
joint counts, pain and ESR87. Other csDMARD such as
sulfasalazine, leflunomide and cyclosporine have
demonstrated modest benefits89. Sulfasalazine is rarely
prescribed for children younger than 2 years, due to
paucity of safety data in this group90. Although axial
disease is relatively common in older children it tends
to run a milder course. Pharmacological treatment
should be considered in patients who experience axial
symptoms or show progressive limitation of spinal mo-
bility. Anti-TNF therapy is highly effective in adult PsA
patients with inadequate response to NSAIDs, as as-
sessed both by symptoms and by MRI evidence of in-
flammation91.
15. tnfi are recommended for refractory jpsA.
other biologics may be considered in case of
inadequate response and/or major cutaneous
involvement 
Etanercept and adalimumab have been used success-
fully in jPsA and juvenile spondyloarthritis patients re-
fractory to conventional treatment18,40,92. However, for
skin involvement, it seems that the efficacy of etaner-
cept on psoriasis and psoriatic nail disease may be lo -
wer or, at least, of slower onset, than for the antibo dies
NSAIDs±MTX± IAG injections
Diseasecontrol within3-6 monthsPoorprognosticfeatures
Change oradd anothercsDMARD
Switchto a2nd TNFi 
Add  TNFi  
Disease controlwithin 3 month
Disease controlwithin 3 month
Continue
Continue
Consider switching toanother MOA bDMARD
StopNSAIDsContinue MTXYES YES
YES
YES
NO
NO
NO
NO
NSAIDs
±MTX
± IAG injections
Disease
control within
3-6 months
Poor
prognostic
features
Change or
add another
csDMARD
Switch
to a
2nd TNFi 
Add  TNFi  
Disease control
within 3 month
Disease control
within 3 month
Continue
Continue
Consider switching to
another MOA bDMARD
Stop
NSAIDs
Continue MTX
YES
YES
YES
YES
NO
NO
NO
NO
fIgurE 4. Enthesitis-related arhtritis  
Legend: NSAIDs – non steroidal anti inflammatory drugs; MTX-methotrexate; GC – glucocorticoids; csDMARDs – classic synthetic
Disease Modifying Anti Rheumatic Drugs; TNFi – Tumour Necrosis Factor inhibitor; bDMARD – biologic Disease Modifying Anti
Rheumatic Drug; MOA – mode of action
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targeting TNF93. Other biological agents have been as-
sessed in PsA but there is scarce data to ascertain effi-
cacy and safety profile for their use in children56,69,94.
However, ustekinumab, a monoclonal antibody against
IL-12/23, is already approved for adults with PsA and
for psoriasis in adults and children over 12 years and
is a promising biological agent for jPsA with concomi-
tant moderate–severe psoriasis95. Although switch has
not been formally studied in jPsA, based in studies from
adults, patients resistant to treatment can be switched
to a second TNFi or to a bDMARD with a different
mode of action.
16. Assessment of response and the decision 
to maintain treatment should be performed
no longer than 3 months after starting a
biologic in jpsA patients. biologic treatment
should only be maintained in patients who
achieve at least an Acrped 50 and have
documented improvement of extra-articular
involvement (skin, dactylitis and enthesitis, 
if applicable)
TNF inhibitors have demonstrated efficacy in jPsA,
both for skin, nail, joint involvement, dactylitis and en-
thesitis96. ACRPed 50 response, reduction of the en-
theseal count and the number of digits involved by
50% should be achieved in order to maintain biologi-
cal therapy. The reason to choose a 3-month period is
based on the time to achieve response observed in
phase 3 trials with biologics in jPsA.
Disease control within 1 monthMTX or anothercsDMARD (SZP or LEF) NO
NO
NO YES
NODisease 
ControlContinue
Switch to a 2nd TNFi 
Add a TNFi
Disease control
Disease control
Continue
Continue
Continue
YES
YES
YESNO
NSAIDs± IAG injections Psoriatic spondylitisPeripheral arthritisDactylitis
Consider switching to another MOA bDMARD 
Disease 
control within 
1 month
MTX or 
another
csDMARD 
(SZP or LEF)
NO
NO
NO YES
NO
Disease 
ControlContinue
Switch to a 
2nd TNFi 
Add a TNFi
Disease control
Disease control
Continue
Continue
Continue
YES
YES
YES
NO
NSAIDs
± IAG 
injections
Psoriatic 
spondylitis
Peripheral 
arthritis
Dactylitis
Consider switching to 
another MOA bDMARD 
fIgurE 5. Juvenile Psoriatic Arhtritis  
Legend: NSAIDs – non steroidal anti inflammatory drugs; MTX-methotrexate; GC – glucocorticoids; csDMARDs – classic synthetic
Disease Modifying Anti Rheumatic Drug; SZP – Sulfasalazine; LEF – leflunomide; TNFi – Tumour Necrosis Factor inhibitor; MOA –
mode of action
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tApErIng And stoppIng bIoLogIcAL thErApy 
17. reducing and stopping biologic therapy
might be attempted if sustained remission 
is achieved and maintained for more than 
24 months
The paramount goal of JIAs treatment is to achieve
inactive disease and remission, with or without medi-
cation. Inactive disease is defined as no joints with ac-
tive arthritis, no fever, rash, serositis, splenomegaly, or
generalized lymphadenopathy attributable to JIA; no
active uveitis as defined by the SUN Working Group;
ESR or CRP level within normal limits or, if elevated,
not attributable to JIA; PhGA indicating no active disea -
se (i.e. best score attainable on the scale used) and du-
ration of morning stiffness of <15 minutes97. Inactive
disease can also be defined for oJIA or pJIA using
JADAS cut-off scores15.
Six continuous months of inactive disease on medi -
ca tion defines clinical remission on medication, while
12 months of inactive disease off all anti-arthritis (and
anti-uveitis) medications defines clinical remission off
medication98. There is some evidence that at least one-
-third of patients can successfully undergo withdra wal
of TNFi treatment for at least 12 months, but further
studies are needed to accurately identify these patients99.
It is unclear which approach is more advantageous, if to
stop treatment abruptly or to taper it gradually.
sAfEty consIdErAtIons
Before starting and while on biologics, safety procedures
and specific contraindications must be respected.
18. All patients must be screened for
tuberculosis, human immunodeficiency virus,
hepatitis b and c virus infection prior to
biological therapy 
The risk of developing tuberculosis (TB) is high among
individuals treated with bDMARDs. With regard to
TNFi the relative risk in adults is increased from 1.6 up
to more than 25 times, depending on the clinical set-
ting and the TNFi used, being higher for monoclonal
antibodies100-102. Nevertheless, the existing data support
a lower risk of developing TB among children who re-
ceive TNF antagonist therapies in industrialized coun-
tries, probably as a consequence of the lower preva-
lence of latent infection with Mycobacterium tuberculo-
sis in children as compared to adults103,104 (See Annexe
I for screening and prophylaxis details).
Children with JIAs may be accidentally found to suf-
fer from human immunodeficiency virus (HIV) infec-
tion or chronic hepatitis B or C. The presence of such
an underlying chronic infection generates a number of
practical issues regarding management of their arthri-
tis with csDMARDs and bDMARDs105 (See Annexe I for
risk and screening details).
19. biological therapy should be discontinued
prior to elective surgery and re-introduced
only in the absence of infection, and after
satisfactory healing of surgical wound
A temporary suspension of the biological agent before
elective surgery is recommended in order to reduce the
risk of postoperative infection106. The half-live of the
drug should be taken into account when planning pre-
surgical interruption (Table IV). Almost complete eli -
mination of the drug occurs after 5 half-lives. The type
of surgery and the risk of infection based on the surgi-
cal procedure, as well as the general health of the pa-
tient and co-medication must be also considered. In
case of an urgent surgery, biologic treatment should be
temporarily withdrawn and the use of prophylactic an-
tibiotics considered. Biologics can be restarted after sa -
tisfactory healing of the surgical wound, and signs of in-
fection are excluded.
20. biological therapy should not be 
initiated in presence of active infection 
and must be discontinued until any serious
infection is resolved
The use of biological agents in patients with history of
chronic or recurrent infections, or with conditions that
predispose to infection, must be cautious. Patients who
tAbLE Iv. dIscontInuAtIon of bIoLogIcAL 
thErApy bEforE An ELEctIvE surgEry
Suspension
Biologic Half-live before surgery
Abatacept 13 (8-25) days 8 weeks
Adalimumab 10-14 days 4 weeks
Anakinra 4-6 hours 24-48 hours
Canakinumab 23-26 days 8 weeks
Certolizumab 14 days 4 weeks
Etanercept 3-4 days 2 weeks
Golimumab 12 (7-20) days 8 weeks
Infliximab 8-10 days 4 weeks
Rituximab 32 (14-62) days 24 weeks
Tocilizumab 8-14 days 4 weeks
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develop an infection during biological treatment must
be carefully evaluated (search for constitutional sym -
ptoms, order complete blood count, CRP, bacteriologi -
cal tests and appropriate imaging studies) and the
admi nistration of the biologic must be postponed un-
til the infectious episode is controlled. In case of se -
rious bacterial infection (eg: bacteraemia/sepsis, abs -
cess/cutaneous ulcer, pneumonia, cellulitis, dissemina -
ted impetigo, bacterial endocarditis, acute pyelonephri-
tis, intra-abdominal infection, osteomyelitis, septic
arthritis, peritonitis, acute sinusitis with fever) or po-
tentially serious or complicated viral infection (eg: EBV,
CMV, parvovirus, varicella) consider also temporary
withdrawal of the biologic.
contrAIndIcAtIons
Absolute and relative contraindications, as well as rea-
sons for temporary interruption of biologics are listed
in Table V.
concLusIons
Biological therapy represents an advance in the treat-
ment of JIA. The benefits and risks of these agents are
known mainly from RCTs, but registries add relevant
information to that knowledge. Precautions related to
adverse events associated with the use of biologicals,
namely infections, injection site reactions and potential
risks associated to live vaccines should be taken into ac-
count when these drugs are prescribed.
1. TOOLS FOR ASSESSING DISEASE ACTIVITY:
Joint disease - 1) Active joint count (presence of swelling
not due to deformity, or limitation of motion with pain,
tenderness or both) and/or 2) Juvenile Arthritis Dis-
ease Activity Score (JADAS), a composite index that
uses the arithmetic sum of the active joint count as-
sessed in 71 (JADAS71), 27 (JADAS27), or 10 (JADAS10)
joints, physician global assessment (PhGA) of disease
activity, parent/patient global assessment (PGA) of well-
being and erythrocyte sedimentation rate (ESR) nor-
malized to a 0–10 scale14. Clinical JADAS (cJADAS),
without laboratory measures, is an alternative with
good correlation with JADAS-ESR. JADAS cutoff values
identifying different states of JIA activity for oligo and
polyarthritis are shown in Table II15. Specific cut-off
values for sJIA, ERA or jPsA have not yet been esta -
blished.
Enthesitis - Entheseal count is suitable for documenting
enthesitis activity.
Systemic features: Systemic symptoms (fever, rash,
splenomegaly, lymphadenopathy) and inflammatory
markers (raised ESR and C-reactive protein) were
found to be the most important domains to evaluate
systemic features
2. PROGNOSTIC FACTORS
Children with persistent oJIA have a substantially bet-
ter outcome than those with either sJIA or pJIA with re-
gard to remission, disability and structural damage72.
Diagnostic delay, greater severity and extension of
tAbLE v. contrAIndIcAtIons for bIoLogIcAL thErApy
Absolute contraindications Relative/temporary contraindications
Active infection, including tuberculosis and HBV+ Sexually active female without an effective contraception 
Serious and/or recurrent infections Known or predicted pregnancy 
Recent history (<5 years) of malignancy Breastfeeding 
Demyelinating disease or optic neuritis* Acute infection 
Cardiac insufficiency class III/IV* HCV infection
Known hypersensitivity to the active substance or excipients HIV infection
Concomitant use of two or more biologics Live attenuated vaccines in the last month 
Scheduled major surgery 
Active liver disease/hepatic impairment with AST or
ALT>5x upper normal range
HBV – hepatitis B virus; HCV – hepatitis C virus; HIV – human immunodeficiency virus; AST – aspartate transaminase; ALT – alanine 
transaminase. 
*Contraindication for TNFi
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arthritis at onset, symmetric disease, early hip or wrist
involvement, involvement of cervical spine, the pre -
sence of RF and/or anti-cyclic citrullinated peptide an-
tibodies, early age at onset, female gender, family his-
tory of rheumatic disease and prolonged active disease
are predictors of poor outcome73, 74.
This article has been copublished in the issue no.4 of Acta
Pediátrica Portuguesa 2016 (Acta Pediatrica Port 2016;
47: 4 Oct/Dec)
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AnnEXE I
scrEEnIng for chronIc InfEctIons bEforE stArtIng A bIoLogIc In chILdrEn And AdoLEscEnts
wIth JIA
TUBERCULOSIS
Screening for latent tuberculosis infection (LTBI) or active TB includes:
1. Full clinical history and physical examination comprising ethnicity, place of birth, history of recent exposure
to TB, previous TB and its treatment, travel to endemic areas, any additional risk factors.
2. Chest radiography (findings suggestive of previous or active TB)
3. Tuberculin Skin Test (TST) should be performed before initiating any immunosuppressive treatment and re-
peated at screening prior to biological therapy.  TST is considered positive in immunocompetent, BCG-vacci-
nated children if > 10 mm; and in children on immunosuppressive treatment or non-vaccinated children <= 5
years old if > 5 mm induration, taking epidemiological risk factors into account. 
4. Interferon-g release assay (IGRA)
Four meta-analyses of pediatric IGRA studies concluded that IGRAs have higher specificity for TB infection than
the TST, particularly in settings of low TB burden and among BCG-vaccinated children. One meta-analysis esti-
mated pooled specificities of 100%, 90%, and 56% for QFT, T-SPOT, and TST, respectively. IGRAs do not offer
greater sensitivity than the TST. Sensitivity for both tests range between 62% and 90% for children with culture-
-confirmed TB disease. Furthermore, like the TST, IGRAs have poor sensitivity among immunocompromised pa-
tients and cannot differentiate LTBI from disease. Some studies show a better sensitivity for T-SPOT than QFT in
immunocompromised patients. Of note, a lack of data on IGRA performance in children aged 0 to 4 years has led
to hesitancy to use these assays in this age group. 
5. The child should be referred to a Paediatrician or Paediatric Infectious Disease specialist or Paediatrics Pulmo-
nologist with expertise in TB diagnosis and treatment if any of the screening procedures is positive, age < 5 years
old or in case of doubt.
6. Preventive chemotherapy against TB is indicated in all patients with evidence of LTBI 
When TST and IGRA tests gave discordant results, the result of IGRA should prevail over TST in BCG-vacci-
nated children, especially if age ≥ 5 years. On the other hand, in non-vaccinated children a positive test result
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(either TST or IGRA) should qualify for the individual to undergo preventive therapy. In this case of LTBI 
diagnosis, biological therapy should be postponed for 4 weeks after MT therapy is started. In patients with
active tuberculosis biological therapy should be initiated after a full course of TB treatment has been completed.
If JIA activity is very high an earlier initiation of biological treatment can be considered but never before the
end of the first 2 months of TB treatment.
Patients should be carefully monitored for TB symptoms throughout the period they receive treatment with bio -
logical agents and for six months after discontinuation. Repeated testing for latent MT infection (every year) may
be considered, especially in patients treated with anti-TNF monoclonal antibodies. However, repeated TST should
be avoided as results might be distorted by boosting.
FUNGAL INFECTIONS
Unlike screening for TB, there are no guidelines on screening for fungal infections, such as Histoplasma capsula-
tum and Coccidioides immitis, which both have latent infections similar to TB, and so in endemic areas, serological
screening should be performed before initiating a biologic. Furthermore, Listeria monocytogenes is an intracellu-
lar pathogen acquired via the ingestion of contaminated meats and dairy products. Newly acquired (and fatal) ca -
ses of listeriosis have occurred in patients who were taking TNFi. Patients should avoid unpasteurized dairy pro -
ducts while on biologic agents. 
HEPATITIS B VIRUS INFECTION
All patients starting DMARDs (biological or non-biological) should be screened for HBV infection with HBsAg,
anti-HBc and anti-HBs. 
1. An hepatologist should be consulted if JIA patients are found to have current or past HBV infection 
2. Antiviral therapy should be initiated before DMARD therapy in patients with chronic HBV infection (HBsAg+)
3. Patients with past HBV infection (HBsAg−/anti-HBc+) do not need prophylactic antiviral treatment. Howe ver,
increased vigilance for HBV reactivation is needed (frequent measurement of AST/ALT, HBV DNA levels). 
4. If HBV DNA is found to be positive, initiation of antiviral therapy with the newer agents is recommended. 
Hepatitis C virus infection 
1. HCV screening is recommended before leflunomide and methotrexate use in the presence of hepatitis risk fac-
tors, and for all patients starting biologics
2. If HCV screening is positive the result should be confirmed by HCV RNA testing. 
3. For patients found to have chronic HCV infection, referral to an hepatologist is recommended. Treatment de-
cision should take into account several factors, for example the severity of liver disease, the likelihood of res -
ponse to therapy (genotype-1 vs non-1), the likelihood of antiviral therapy-induced side effects (exacerbation
of arthritis, psoriasis etc.), the presence of co-morbid conditions (cytopenias, renal dysfunction, mood disor-
ders, etc.) and patient/parents willingness.
4. In general, methotrexate and leflunomide are contraindicated in HCV-infected patients, although data regar -
ding their safety for patients with mild or moderate liver fibrosis are not available. 
5. Biological agents can be used in patients with non-advanced liver disease (Child–Pugh class A).  
6. In the most recent ACR recommendations, etanercept was suggested as the preferred agent for patients with RA
and chronic hepatitis C (level of evidence C). Monotherapy with rituximab is also a potential agent to use for
such patients. 
HUMAN IMMUNODEFICIENCY VIRUS INFECTION
1. Patients should be screened for HIV infection before starting a biologic agent. If positive an expert in pediatric
HIV infection should be consulted.
2. TNFi therapy is a viable alternative for refractory JIA patients with HIV infection, without advanced disease.
